Bifogade filer
Kurs
-0,50%
Likviditet
0,32 MSEK
Prenumeration
Kalender
Tid* | ||
2026-02-05 | 08:00 | Bokslutskommuniké 2025 |
2025-10-23 | 08:00 | Kvartalsrapport 2025-Q3 |
2025-07-16 | 08:00 | Kvartalsrapport 2025-Q2 |
2025-05-06 | 08:00 | Kvartalsrapport 2025-Q1 |
2025-02-06 | 08:00 | Bokslutskommuniké 2024 |
2024-12-18 | - | Extra Bolagsstämma 2025 |
2024-10-24 | - | Kvartalsrapport 2024-Q3 |
2024-07-17 | - | Kvartalsrapport 2024-Q2 |
2024-05-08 | - | Kvartalsrapport 2024-Q1 |
2024-04-29 | - | X-dag ordinarie utdelning ORX 0.00 SEK |
2024-04-26 | - | Årsstämma |
2024-02-08 | - | Bokslutskommuniké 2023 |
2023-11-02 | - | Kvartalsrapport 2023-Q3 |
2023-10-26 | - | Extra Bolagsstämma 2023 |
2023-07-18 | - | Kvartalsrapport 2023-Q2 |
2023-04-27 | - | Kvartalsrapport 2023-Q1 |
2023-04-19 | - | X-dag ordinarie utdelning ORX 0.00 SEK |
2023-04-18 | - | Årsstämma |
2023-01-26 | - | Bokslutskommuniké 2022 |
2022-11-03 | - | Kvartalsrapport 2022-Q3 |
2022-07-14 | - | Kvartalsrapport 2022-Q2 |
2022-04-28 | - | Kvartalsrapport 2022-Q1 |
2022-04-22 | - | X-dag ordinarie utdelning ORX 0.00 SEK |
2022-04-21 | - | Årsstämma |
2022-01-27 | - | Bokslutskommuniké 2021 |
2021-11-03 | - | Kvartalsrapport 2021-Q3 |
2021-07-15 | - | Kvartalsrapport 2021-Q2 |
2021-04-29 | - | Kvartalsrapport 2021-Q1 |
2021-04-14 | - | X-dag ordinarie utdelning ORX 0.00 SEK |
2021-04-13 | - | Årsstämma |
2021-01-28 | - | Bokslutskommuniké 2020 |
2020-11-04 | - | Kvartalsrapport 2020-Q3 |
2020-07-16 | - | Kvartalsrapport 2020-Q2 |
2020-05-19 | - | Extra Bolagsstämma 2020 |
2020-04-28 | - | Kvartalsrapport 2020-Q1 |
2020-04-17 | - | X-dag ordinarie utdelning ORX 0.00 SEK |
2020-04-16 | - | Årsstämma |
2020-01-30 | - | Bokslutskommuniké 2019 |
2019-10-24 | - | Kvartalsrapport 2019-Q3 |
2019-07-11 | - | Kvartalsrapport 2019-Q2 |
2019-05-02 | - | Kvartalsrapport 2019-Q1 |
2019-04-14 | - | X-dag ordinarie utdelning ORX 0.00 SEK |
2019-04-11 | - | Årsstämma |
2019-01-30 | - | Bokslutskommuniké 2018 |
2018-10-25 | - | Kvartalsrapport 2018-Q3 |
2018-07-11 | - | Kvartalsrapport 2018-Q2 |
2018-04-26 | - | Kvartalsrapport 2018-Q1 |
2018-04-13 | - | X-dag ordinarie utdelning ORX 0.00 SEK |
2018-04-12 | - | Årsstämma |
2018-01-25 | - | Bokslutskommuniké 2017 |
2017-10-19 | - | Kvartalsrapport 2017-Q3 |
2017-07-11 | - | Kvartalsrapport 2017-Q2 |
2017-04-20 | - | Kvartalsrapport 2017-Q1 |
2017-04-07 | - | X-dag ordinarie utdelning ORX 0.00 SEK |
2017-04-06 | - | Årsstämma |
2017-01-26 | - | Bokslutskommuniké 2016 |
2016-10-20 | - | Kvartalsrapport 2016-Q3 |
2016-07-12 | - | Kvartalsrapport 2016-Q2 |
2016-04-21 | - | Kvartalsrapport 2016-Q1 |
2016-04-18 | - | X-dag ordinarie utdelning ORX 0.00 SEK |
2016-04-15 | - | Årsstämma |
2016-01-28 | - | Bokslutskommuniké 2015 |
2015-10-22 | - | Kvartalsrapport 2015-Q3 |
2015-07-10 | - | Kvartalsrapport 2015-Q2 |
2015-04-23 | - | Kvartalsrapport 2015-Q1 |
2015-04-16 | - | X-dag ordinarie utdelning ORX 0.00 SEK |
2015-04-15 | - | Årsstämma |
2015-01-29 | - | Bokslutskommuniké 2014 |
2014-10-22 | - | Kvartalsrapport 2014-Q3 |
2014-10-22 | - | Analytiker möte 2014 |
2014-07-11 | - | Kvartalsrapport 2014-Q2 |
2014-04-25 | - | Kvartalsrapport 2014-Q1 |
2014-04-16 | - | X-dag ordinarie utdelning ORX 0.00 SEK |
2014-04-15 | - | Årsstämma |
2014-01-30 | - | Bokslutskommuniké 2013 |
2013-10-23 | - | Kvartalsrapport 2013-Q3 |
2013-08-06 | - | Extra Bolagsstämma 2013 |
2013-07-12 | - | Kvartalsrapport 2013-Q2 |
2013-04-26 | - | Kvartalsrapport 2013-Q1 |
2013-04-12 | - | X-dag ordinarie utdelning ORX 0.00 SEK |
2013-04-11 | - | Årsstämma |
2013-03-13 | - | 15-7 2013 |
2013-01-31 | - | Bokslutskommuniké 2012 |
2012-10-25 | - | Kvartalsrapport 2012-Q3 |
2012-09-21 | - | 15-7 2012 |
2012-07-13 | - | Extra Bolagsstämma 2012 |
2012-07-12 | - | Kvartalsrapport 2012-Q2 |
2012-05-03 | - | Kapitalmarknadsdag 2012 |
2012-04-27 | - | Kvartalsrapport 2012-Q1 |
2012-04-12 | - | X-dag ordinarie utdelning ORX 0.00 SEK |
2012-04-11 | - | Årsstämma |
2012-01-31 | - | Bokslutskommuniké 2011 |
2011-11-09 | - | Kvartalsrapport 2011-Q3 |
2011-08-10 | - | Kvartalsrapport 2011-Q2 |
2011-05-04 | - | Kvartalsrapport 2011-Q1 |
2011-04-08 | - | X-dag ordinarie utdelning ORX 0.00 SEK |
2011-04-07 | - | Årsstämma |
2011-02-16 | - | Extra Bolagsstämma 2011 |
2011-02-16 | - | Bokslutskommuniké 2010 |
2010-11-10 | - | Kvartalsrapport 2010-Q3 |
2010-08-20 | - | Kvartalsrapport 2010-Q2 |
2010-05-05 | - | Kvartalsrapport 2010-Q1 |
2010-04-22 | - | X-dag ordinarie utdelning ORX 0.00 SEK |
2010-04-21 | - | Årsstämma |
2010-02-17 | - | Bokslutskommuniké 2009 |
2009-11-10 | - | Kvartalsrapport 2009-Q3 |
2009-08-21 | - | Kvartalsrapport 2009-Q2 |
2009-05-06 | - | Kvartalsrapport 2009-Q1 |
2009-04-24 | - | X-dag ordinarie utdelning ORX 0.00 SEK |
2009-04-23 | - | Årsstämma |
Beskrivning
Land | Sverige |
---|---|
Lista | Small Cap Stockholm |
Sektor | Hälsovård |
Industri | Läkemedel & Handel |
Uppsala, Sweden – July 10, 2024 – Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY) announces that it has received a Gold Sustainability Rating by EcoVadis, one of the world´s most trusted provider of business sustainability ratings. The highly revered award places the company in the top 5 percent of all 70,000 businesses worldwide that are reviewed by EcoVadis each year.
This top rating is based on Orexo AB’s first year of reporting to EcoVadis and mainly includes sustainability data related to the business in Sweden, covering Group headquarters functions, R&D, Regulatory Affairs, Quality & She, and Supply Chain.
It showcases the outcome of dedicated sustainability activities undertaken over the last several years across social, environmental and governance areas of Orexo AB. And it shows how the employees and partners are working together to achieve successes across four areas: Environment, Labor and Human Rights, Ethics and Sustainable Procurement.
Nikolaj Sørensen, President and CEO, of Orexo, said, “Achieving this rating is a privilege and we will continue setting ambitious goals in our active pursuit of an even more sustainable and inclusive future for everyone. This is central to our values-based approach to growth and underpins optimal outcomes for patients, investors, the company and society more broadly.”
Contacts:
Nikolaj Sørensen, President and CEO
Lena Wange, IR & Communications Director
+46 (0)18 780 88 00
Related links
EcoVadis: https://ecovadis.com/
Sustainability at Orexo: https://orexo.com/sustainability/
About Orexo
Orexo is a Swedish pharmaceutical company with over 25 years of experience developing improved pharmaceuticals based on proprietary formulation technologies that meet large medical needs. On the US market, Orexo provides innovative treatment solutions for patients suffering from opioid use disorder and adjacent diseases. Products targeting other therapeutic areas are developed and commercialized worldwide with leading partners. Total net sales in 2023 amounted to SEK 639 million, and the number of employees to 116. Orexo is listed on Nasdaq Stockholm's main list and is available as an ADR on OTCQX (ORXOY) in the US.
For more information about Orexo please visit www.orexo.com. You can also follow Orexo on X, LinkedIn, and YouTube.
The information was submitted for publication at 8 a.m. CET, on July 10, 2024.